NCT03627780 (ponv) is a clinical trial of DNA extraction in Genetic Predisposition to Disease, sponsored by Instituto do Cancer do Estado de São Paulo.

Who is sponsoring NCT03627780?

NCT03627780 is sponsored by Instituto do Cancer do Estado de São Paulo.

What drugs are being tested in NCT03627780?

Interventions in NCT03627780: DNA extraction.

What condition does NCT03627780 study?

NCT03627780 studies Genetic Predisposition to Disease, Postoperative Nausea, Polymorphism, Genetic.

Is NCT03627780 still recruiting?

NCT03627780 is currently completed. Last updated 19 May 2021.

Last reviewed 2021-05-19 · How we verify

NCT03627780: ponv

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Polymorphism and Post Operative Nausea and Vomiting (PONV)

Completed Last updated 19 May 2021

What this trial tests

trial testing DNA extraction in Genetic Predisposition to Disease in 300 participants. Completed in 1 March 2020.

Timeline

2 January 2017

Primary endpoint
1 March 2020

1 March 2020

Quick facts

Lead sponsor	Instituto do Cancer do Estado de São Paulo
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	2 January 2017
Primary completion	1 March 2020
Estimated completion	1 March 2020
Sites	2 locations across Brazil

Drugs / interventions tested

DNA extraction

Conditions studied

Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →
Postoperative Nausea — all drugs for Postoperative Nausea →
Polymorphism, Genetic — all drugs for Polymorphism, Genetic →

Sponsor

Instituto do Cancer do Estado de São Paulo — full company profile →

Who can join

18 and older, any sex, with Genetic Predisposition to Disease or Postoperative Nausea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nausea and vomiting affects 25-30% of individuals in the post-operative period and can reach more than 70-80% in high-risk patients. inherited factors may play a significant role in individual susceptibility and clinical research on hereditary factors involved in the pathogenesis of Postoperative nausea and vomiting (PONV) and chemotherapy nausea and vomiting (CINV) is relatively new. The aim of this study is to investigate whether inter-individual differences related to PONV are associated with genetic factors. 300 patients will be evaluated in postoperative oncological surgeries. The peripheral leukocyte DNA will be extracted by the Salting Out Procedure method and processed to genotyping for 48 SNPs from 15 candidate genes by real-time PCR by the Taqman method. The possible associations with demographic data and factors related to surgery will be analyzed by univariate and multivariate analysis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical, ethnic and genetic risk factors associated with postoperative nausea and vomiting in patients undergoing cancer surgery: a case-control study.
Grigio TR, Furuya TK, Slullitel A, Murillo Carrasco AG, et al · · 2025 · PMID 40385041 · DOI 10.62347/dgrm3907

Verify or expand the search:

Other trials of DNA extraction

Trials testing the same drug.

NCT04561895 — Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients · completed
NCT04339725 — Gut Microbiota Metagenomics for Chronic Liver Disease · unknown
NCT01065233 — Pangenomic Study During Alcoholic Cirrhosis · completed

Other recruiting trials for Genetic Predisposition to Disease

Currently open trials in the same condition.

NCT06962059 — Healthy Volunteers Study · recruiting
NCT07018128 — Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure · NA · recruiting
NCT06399666 — Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation · recruiting
NCT05772559 — Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, · recruiting
NCT05759143 — Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing · NA · recruiting

Other Instituto do Cancer do Estado de São Paulo trials

Trials by the same sponsor.

NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
NCT05996367 — Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03627780 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
Last refreshed: 19 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03627780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing